

# Background

- Simula and UC Berkeley have had an ongoing scientific collaboration since 2017.
  - UC Berkeley developing advanced cardiac in vitro test methods
  - Simula has developed *in silico* methods to probe cardiac function

 Organos Inc is a commercial venture that has spun out of this collaboration, and aims to develop organ chip technology combined with advanced analysis algorithms for industrial applications.

### **Mission**

Revolutionizing cardiac drug development



# **Development / Funding Timeline**





### Cardiovascular Health – An Immense and Growing Problem

#1

Killer Worldwide

\$900B

Social and economic burden globally

65M

Patients with heart failure


50% 5-year mortality





## **Unmet Need for Cardiovascular Therapeutics**






Limited treatment options available

Insufficient ongoing innovation




### How to discover the next generation of cardiac drugs



Phenotypic screens essential




Current screens do not capture cardiac tissue-level phenotypes



**Need for novel phenotypic HTS** 



# A New Pathway for Cardiac Drug Discovery and Development






### **Organos - Phenotypic Screening with Human Cardiac Microtissues**

#### **Microfabrication**



Miniaturized form factor amenable for HTS

#### **Human Heart Muscle**



Human tissue and human disease models

#### **Computations**




Enabling analysis of complex data readouts



## Organos - Harnessing the Power of the Human Heart Beat

#### **Discovery**

#### Heart Muscle Array High-throughput





500 μm

- High throughput and high content systems
- Electrical / mechanical / biochemical assays

#### **Development**

Heart Muscle Chip High Content






150 µm



### Platform for Phenotypic Data Generation




- Optical non-destructive measurements of the human heart beat dynamics
- Uniquely captures critical coupled electromechanical physiological pathways




# Platform Technologies for Cardiac Phenotypic Screening


#### **Assessing Contractility**



#### **Understanding Arrhythmia**



#### **Chronic Polytherapy**




Demonstrated utility across a range of pharmaceutical cardiac applications




### A Collaboration to Transform Data into Knowledge









HTS multiplexed cardiac measurements

Knowledge and data based *in silico* models Phenotypic pattern recognition

Understanding compound mechanism of action

Combinatorial effect screening

#### **External Validation**



**\$12.4M + non-dilutive**: \$8.5M+ in grants & **\$3.9M**+ in NIH / CIRM direct funding



















\$100K contract with one of the world's largest biotech firms









## The Organos Team



Samuel Wall, Ph.D Founder / CSO





Kevin E. Healy, Ph.D. Founder / COB / SAB Professor UC Berkeley





Julia Schaletzky, Ph.D. Cardiac Drug Discovery





Verena Charwat, Ph.D. Principal Scientist



Brian Siemons Scientist/Tech.







Brennan Kandalaft Research Associate







### The Organos Team

#### **Advisors**

#### Business Development



Michael W. Henry,



**Business Development** 



Mimi Hancock, PhD



FRAZIER

Clinical Cardiology



Theodore Abraham, MD Professor of Cardiology



Cardiac Cell Biology



Andrew Edwards, Ph.D. Professor UC Davis



Cardiac
Tissue Engineering



Nathaniel Huebsch, Ph.D. Professor Wash U. (St Louis)



Computational Cardiac Physiology



Aslak Tveito, Ph.D. CEO Simula/UiO Professor





# **Future Perspectives**

### Simula / UC Berkeley

 Continued scientific work and collaboration on joint projects and funding opportunities.

#### **Organos**

- Well funded to develop vitro side of the system through US sources
- Development and validation work on drug discovery
- Ongoing contract work with large Pharma partner
- Approach capital markets in late 2022 / early 2023 for growth funding
- Find avenues to grow computational side in Norway

